MYGN Misses Q1 Targets, Stock Tanks

Myriad Genetics Q1 earnings missed revenue targets, with sales up 2.3% to $204M but missing expectations. Adjusted EPS loss worsened to -$0.09, and the stock plummeted 16.2%. Despite negative EBITDA and operating margins, the company maintained full-year revenue guidance and raised EBITDA outlook. Investors reacted negatively, sending shares down to $4.21. Despite recent slowdown, analysts predict 5.9% growth in the next year, topping the sector average. The company, a genetic testing pioneer, is looking to capitalize on cancer testing and prenatal health improvements. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/8de2b2c80db6a4f6